Novo Nordisk execs field questions from analysts at their Capital Markets Day. (Credit: Novo Nordisk)

No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

No­vo Nordisk’s oral amy­cretin showed a 13.1% weight loss in pa­tients af­ter just 12 weeks in a small Phase I tri­al, the com­pa­ny re­vealed at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.